Patient Appreciation Event – Save up to 50%! SHOP NOW >

Reloxin won't let Botox Relax


There's been much talk about the possibility of Reloxin entering the U.S. Aesthetic Market as a strong competitor to Botox.

Here's what we know thus far:

The FDA announced that it is reviewing Reloxin, an anti-wrinkle injectable for domestic approval. Reloxin is already available for aesthetic use in 23 countries.

Botox Cosmetic, marketed by Allergan, is the only drug of its kind available in the U.S. market and has a well-established safety and efficacy history. With the possibility of Reloxin hitting the U.S. Market, Allergan is certainly in for competition.

Although certain clinical studies have shown that Reloxin takes effect faster, may last longer and have fewer side effects than Botox, Reloxin will have to compete in price, efficacy and service to attract aesthetic consumers to their product.

Botox in general has a remarkable safety profile. The product was first approved nearly 20 years ago and today benefits 21 different patient populations across more than 75 countries, ranging from very debilitated and compromised patients to healthy individuals who want to look and feel their best.

There will be those people that will want to try Reloxin, while others will remain loyal to the drug (Botox) that they have trusted in delivering results.

Public Comments

Subscribe Here!